New hope for Hard-to-Treat breast cancer: Dato-DXd takes on chemo

NCT ID NCT05374512

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests a new drug called Dato-DXd against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. About 644 participants will be randomly assigned to receive either Dato-DXd or one of several chemotherapy drugs. The main goals are to see if Dato-DXd delays cancer growth or improves survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: Datopotamab deruxtecan (Dato-DXd)
What this could lead to: If successful, Dato-DXd could offer a new, more effective first-line treatment option for people with metastatic triple-negative breast cancer who cannot take immunotherapy.
What could go wrong: This is a phase 3 trial, but results are not yet available. The drug may not improve survival or could have side effects like other chemotherapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

644 people

The number who actually took part.

Started

May 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age 1. Participant must be ≥ 18 years at the time of screening. Type of Participant and Disease Characteristics 2. Histologically or cytologically documented locally recurrent inoperable TNBC, which cannot be treated with curative intent, or metastatic TNBC. TNBC is defined as: * Negative for ER with \< 1% of tumour cells positive for ER on IHC. * Negative for progesterone receptor with \< 1% of tumour cells positive for progesterone receptor on IHC. * Negative for HER2 with 0 or 1+ intensity on IHC or 2+ intensity on IHC and negative by in situ hybridisation per the ASCO-CAP HER2 guideline 3. No prior chemotherapy or other systemic anti-cancer therapy for metastatic or locally recurrent inoperable breast cancer. 4. Not a candidate for PD-1/PD-L1 inhibitor therapy, defined as: * Participants whose tumours are PD-L1-negative, or * Participants whose tumours are PD-L1-positive and have: 1. relapsed after prior PD-1/PD-L1 inhibitor therapy for early-stage breast cancer, 2. comorbidities precluding PD-1/PD-L1 inhibitor therapy, or 3. no regulatory access to pembrolizumab \[participant's country does not have regulatory approval at the time of screening\]). 5. At least 1 measurable lesion not previously irradiated that qualifies as a RECIST 1.1 TL at baseline and can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI), and is suitable for accurate repeated measurements. 6. ECOG PS 0 or 1 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing. 7. Eligible for one of the chemotherapy options listed as ICC (paclitaxel, nab-paclitaxel, capecitabine, carboplatin, or eribulin), based on DFI and prior taxane exposure, per investigator assessment. 8. Has had an adequate treatment washout period before Cycle 1 Day 1, defined as: * Major surgery: ≥ 3 weeks. * Radiation therapy including palliative radiation to chest: ≥ 4 weeks (palliative radiation therapy to other areas ≥ 2 weeks). * Corticosteroid therapy for central nervous system metastatic disease: \> 3 days. * Anti cancer therapy including hormonal therapy: ≥ 3 weeks (for small molecule targeted agents: ≥ 2 weeks or 5 half-lives, whichever is longer). * Nitrosoureas or mitomycin C: ≥ 6 weeks. * Antibody-based anti cancer therapy: ≥ 4 weeks with the exception of receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors (eg, denosumab for the treatment of bone metastases). * Immunotherapy (non-antibody-based therapy), retinoid therapy: ≥ 2 weeks or 5 times the terminal elimination half-life of the agent, whichever is longer. * Chloroquine/hydroxychloroquine: \> 14 days. 9. Written confirmation of tumour sample needs to be available prior to enrolment and tumour samples should be available prior to randomisation. All participants must have a FFPE metastatic (excluding bone) or locally recurrent inoperable tumour sample (block preferred, or a minimum of 20 freshly cut slides) available, collected ≤ 3 months prior to screening. If neither an adequate FFPE block nor the minimum of 20 slides are available from the most recent biopsy, or if a biopsy is not feasible for safety reasons, and this is clearly documented, an archival tumour specimen obtained before the diagnosis of locally recurrent inoperable or metastatic breast cancer may be submitted, pending approval by the Global Study Team. 10. Participants with a history of previously treated neoplastic spinal cord compression or asymptomatic, stable brain metastases, who require no treatment with corticosteroids or anticonvulsants may be included in the study, if they are no longer symptomatic and have recovered from acute toxic effects of radiotherapy. A minimum of 2 weeks must have elapsed between the end of radiotherapy and Cycle 1 Day 1. A minimum of 3 days must have elapsed between the end of corticosteroid therapy for central nervous system metastatic disease and Cycle 1 Day 1. 11. Adequate organ and bone marrow function within 7 days before randomisation as follows: * Haemoglobin ≥ 9.0 g/dL (red blood cell/plasma transfusion is not allowed within 1 week prior to screening assessment). * Absolute neutrophil count ≥ 1.5 × 10\^9/L (granulocyte colony stimulating factor administration is not allowed within 1 week prior to screening assessment). * Platelet count ≥ 100 × 10\^9/L (platelet transfusion is not allowed within 1 week prior to screening assessment). * Total bilirubin (TBL) ≤ 1.5 × upper limit of normal (ULN) or \< 3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia). * Except in the setting of HBV, Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN for AST/ALT (\< 5 × ULN in participants with liver metastases). See Exclusion Criterion 5 for requirements in the setting of HBV. * Calculated CrCL ≥ 30 mL/minute as determined by Cockcroft Gault 12. Minimum life expectancy of 12 weeks. Sex 13. Male or female. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Reproduction 14. Negative pregnancy test (serum) for women of childbearing potential. 15. Female participants must be at least 1 year post-menopausal, surgically sterile, or using at least 1 highly effective form of birth control (a highly effective method of contraception is defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly.) Women of childbearing potential who are sexually active with a non sterilised male partner must agree to use at least 1 highly effective method of birth control. They should have been stable on their chosen method of birth control for a minimum of 3 months before Cycle 1 Day 1 and continue for at least 7 months after the last dose. Female participants must refrain from egg cell donation or retrieval for their own use, and breastfeeding from enrolment throughout the study and for at least 7 months after the last dose of study drug. Any non sterilised male partner of a woman of childbearing potential must use a male condom plus spermicide (condom alone in countries where spermicides are not approved) throughout this period. 16. Male participants who intend to be sexually active with a female partner of childbearing potential must be surgically sterile or use an acceptable method of contraception from the time of screening throughout the total duration of the study and the drug washout period (at least 6 months after the last dose of study intervention), in addition to the female partner using a highly effective contraceptive method, to prevent pregnancy in a partner. Male participants must not donate or bank sperm during this same time period. Preservation of sperm should be considered prior to randomisation. Not engaging in heterosexual activity (sexual abstinence) for the duration of the study and drug washout period is an acceptable practice, if this is the preferred usual lifestyle of the participant. Periodic or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Informed Consent 17. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. 18. Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of sample for optional genetic research that supports Genomic Initiative. Exclusion Criteria: Medical Conditions 1. As judged by the investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases, uncontrolled hypertension, history of allogeneic organ transplant, and active bleeding diseases, ongoing or active infection, or significant cardiac or psychological conditions), and/or substance abuse which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardise compliance with the protocol. 2. History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence (per investigator assessment). Exceptions include adequately resected non-melanoma skin cancer (basal cell carcinoma of the skin or squamous cell carcinoma of the skin) and curatively treated in situ disease. 3. Persistent toxicities caused by previous anti-cancer therapy, excluding alopecia, not yet improved to Grade ≤ 1 or baseline. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention in the opinion of the investigator may be included (eg, hearing loss). 4. Uncontrolled infection requiring IV antibiotics, antivirals or antifungals; suspected infections (eg, prodromal symptoms); or inability to rule out infections (participants with localised fungal infections of skin or nails are eligible). 5. Known active or uncontrolled hepatitis B or C virus infection. 6. Known human immunodeficiency virus (HIV) infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA, cluster of differentiation (CD)4+ count \> 350 cells/mm3, no history of an acquired immune deficiency syndrome-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications. 7. Uncontrolled or significant cardiac disease including: * Myocardial infarction or uncontrolled/unstable angina within 6 months prior to Cycle 1 Day 1 * Congestive heart failure (New York Heart Association Class II to IV), or * Uncontrolled or significant cardiac arrhythmia, or * Uncontrolled hypertension (resting systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg). 8. Resting ECG with clinically abnormal findings. 9. Uncontrolled hypercalcaemia: \> 1.5 mmol/L (\> 6 mg/dL) ionised calcium, or serum calcium (uncorrected for albumin) \> 3 mmol/L (\> 12 mg/dL), or corrected serum calcium \> ULN, or clinically significant (symptomatic) hypercalcaemia. 10. History of non-infectious ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening 11. Has severe pulmonary function compromise. 12. Leptomeningeal carcinomatosis. 13. Clinically significant corneal disease. 14. Known active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice). Prior/Concomitant Therapy 15. Prior exposure to: * Any treatment (including ADC) containing a chemotherapeutic agent targeting topoisomerase I * TROP2-targeted therapy * Prior treatment with same ICC agent * Chloroquine/hydroxychloroquine without an adequate treatment washout period of \> 14 days prior to randomisation. 16. Any concurrent anti cancer treatment. 17. Concurrent use of systemic hormone replacement therapy (HRT; eg, oestrogen and progesterone). However, concurrent use of hormones for other non-cancer-related conditions (eg, insulin for diabetes or levothyroxine for hypothyroidism) is acceptable. 18. Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 3 weeks of the first dose of study intervention or an anticipated need for major surgery during the study. 19. Receipt of live, attenuated vaccine within 30 days prior to the first dose of study treatment. 20. Concomitant use of chronic systemic (IV or oral) corticosteroids or other immunosuppressive medications except for managing AEs (inhaled steroids or intra articular steroid injections are permitted in this study). Prior/Concurrent Clinical Study Experience 21. Previous randomisation in the present study. 22. Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks prior to first dose of study intervention (unless the safety profile is known prior to randomisation), randomisation into a prior T-DXd or Dato DXd study regardless of treatment assignment, or concurrent enrolment in another clinical study, unless it is an observational (non interventional) clinical study or during the follow-up period of an interventional study. 23. Participants with a known history of severe hypersensitivity reactions to either the drug or any excipients (including but not limited to polysorbate 80) of Dato-DXd or ICC. 24. Known history of severe hypersensitivity reactions to other monoclonal antibodies. Other Exclusions 25. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site). 26. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements. 27. Currently pregnant (confirmed with positive pregnancy test) or breast feeding or planning to become pregnant.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Neoplasm Metastasis triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

Research Site

Duarte, California, 91010, United States
Research Site

Los Angeles, California, 90017, United States
Research Site

San Francisco, California, 94143, United States
Research Site

Grand Junction, Colorado, 81501, United States
Research Site

Longmont, Colorado, 80504, United States
Research Site

New Haven, Connecticut, 06510, United States
Research Site

Washington D.C., District of Columbia, 20010, United States
Research Site

Miami, Florida, 33170, United States
Research Site

Miami, Florida, 33176, United States
Research Site

Atlanta, Georgia, 30322, United States
Research Site

Louisville, Kentucky, 40207, United States
Research Site

Detroit, Michigan, 48201, United States
Research Site

Albuquerque, New Mexico, 87109, United States
Research Site

New York, New York, 10065, United States
Research Site

Charlotte, North Carolina, 28204, United States
Research Site

Winston-Salem, North Carolina, 27103, United States
Research Site

Providence, Rhode Island, 02903, United States
Research Site

Sioux Falls, South Dakota, 57105, United States
Research Site

Memphis, Tennessee, 38120, United States
Research Site

Nashville, Tennessee, 37203, United States
Research Site

Fort Worth, Texas, 76104, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Kingwood, Texas, 77339, United States
Research Site

San Antonio, Texas, 78240, United States
Research Site

Charlottesville, Virginia, 22908, United States
Research Site

Spokane Valley, Washington, 99216, United States
Research Site

Madison, Wisconsin, 53792, United States
Research Site

Buenos Aires, 1058, Argentina
Research Site

CABA, 1414, Argentina
Research Site

CABA, 1426, Argentina
Research Site

CABA, C1113AAE, Argentina
Research Site

Ciudad Autónoma Buenos Aires, C1430EFA, Argentina
Research Site

Ciudad de Buenos Aires, 1426, Argentina
Research Site

Mar del Plata, B7600, Argentina
Research Site

Rosario, 2000, Argentina
Research Site

Anderlecht, 1070, Belgium
Research Site

Ghent, 9000, Belgium
Research Site

Namur, 5000, Belgium
Research Site

Sint-Niklaas, 9100, Belgium
Research Site

Wilrijk, 2610, Belgium
Research Site

Brasília, 71681-603, Brazil
Research Site

Curitiba, 80440-220, Brazil
Research Site

Goiânia, 74000-000, Brazil
Research Site

Jaú, 17210-120, Brazil
Research Site

Porto Alegre, 90619-900, Brazil
Research Site

Porto Alegre, 91350-200, Brazil
Research Site

Rio de Janeiro, 20560-120, Brazil
Research Site

São Paulo, 01246-000, Brazil
Research Site

São Paulo, 01321-001, Brazil
Research Site

São Paulo, 01409-001, Brazil
Research Site

Calgary, Alberta, T2N 5G2, Canada
Research Site

Barrie, Ontario, L4M 6M2, Canada
Research Site

Hamilton, Ontario, L8V 5C2, Canada
Research Site

Ottawa, Ontario, K1H 8L6, Canada
Research Site

Toronto, Ontario, M5G 2M9, Canada
Research Site

Greenfield Park, Quebec, J4V 2H1, Canada
Research Site

Montreal, Quebec, H4A 3J1, Canada
Research Site

Québec, Quebec, G1S 4L8, Canada
Research Site

Beijing, 100021, China
Research Site

Beijing, 100039, China
Research Site

Beijing, 100044, China
Research Site

Bengbu, 233004, China
Research Site

Changchun, 130021, China
Research Site

Changsha, 410008, China
Research Site

Changsha, 410013, China
Research Site

Chengdu, 610000, China
Research Site

Chongqing, 400016, China
Research Site

Guangzhou, 510060, China
Research Site

Guangzhou, 510100, China
Research Site

Hangzhou, 310003, China
Research Site

Hangzhou, 310009, China
Research Site

Hangzhou, 310022, China
Research Site

Hefei, 230031, China
Research Site

Hefei, 230601, China
Research Site

Jinan, 250001, China
Research Site

Jinan, 2501117, China
Research Site

Nanchang, 330009, China
Research Site

Nanjing, 210036, China
Research Site

Shanghai, 200025, China
Research Site

Shanghai, 201318, China
Research Site

Shenyang, 110042, China
Research Site

Shenzhen, 518020, China
Research Site

Tianjin, 300000, China
Research Site

Xi'an, 710004, China
Research Site

Xi'an, 710100, China
Research Site

Zhengzhou, 450008, China
Research Site

Zhengzhou, 450052, China
Research Site

Bordeaux, 33076, France
Research Site

Dijon, 21079, France
Research Site

Limoges, 87042, France
Research Site

Lyon, 69373, France
Research Site

Marseille, 13273, France
Research Site

Montpellier, 34298, France
Research Site

Paris, 75010, France
Research Site

Rouen, 76021, France
Research Site

Saint-Herblain, 44805, France
Research Site

Tours, 37000, France
Research Site

Aschaffenburg, 63739, Germany
Research Site

Bonn, 53111, Germany
Research Site

Frankfurt am Main, 60431, Germany
Research Site

Georgsmarienhütte, 49124, Germany
Research Site

Hanover, 30625, Germany
Research Site

Heilbronn, 74078, Germany
Research Site

Koblenz Am Rhein, 56068, Germany
Research Site

Langen, 63225, Germany
Research Site

München, 81377, Germany
Research Site

Münster, 48149, Germany
Research Site

Wiesbaden, 65199, Germany
Research Site

Budapest, 1062, Hungary
Research Site

Budapest, 1122, Hungary
Research Site

Miskolc, 3526, Hungary
Research Site

Nyíregyháza, 4400, Hungary
Research Site

Zalaegerszeg, 8900, Hungary
Research Site

Bangalore, 560004, India
Research Site

Jaipur, 302022, India
Research Site

Kolkata, 700160, India
Research Site

Nagpur, 440001, India
Research Site

Nashik, 422009, India
Research Site

New Delhi, 110085, India
Research Site

Puducherry, 605006, India
Research Site

Vadodara, 391760, India
Research Site

Borgo San Lorenzo, 50032, Italy
Research Site

Catanzaro, 88100, Italy
Research Site

Genova, 16132, Italy
Research Site

Livorno, 57126, Italy
Research Site

Milan, 20132, Italy
Research Site

Milan, 20141, Italy
Research Site

Modena, 41124, Italy
Research Site

Naples, 80131, Italy
Research Site

Province of Macerata, 62100, Italy
Research Site

Roma, 00137, Italy
Research Site

Rozzano, 20089, Italy
Research Site

Chūōku, 104-0045, Japan
Research Site

Fukushima, 960-1295, Japan
Research Site

Hiroshima, 730-8518, Japan
Research Site

Isehara-shi, 259-1193, Japan
Research Site

Kagoshima, 892-0833, Japan
Research Site

Kashiwa, 277-8577, Japan
Research Site

Kitaadachi-gun, 362-0806, Japan
Research Site

Kōtoku, 135-8550, Japan
Research Site

Kyoto, 606-8507, Japan
Research Site

Matsuyama, 791-0280, Japan
Research Site

Nagoya, 464-8681, Japan
Research Site

Nagoya, 466-8560, Japan
Research Site

Niigata, 951-8566, Japan
Research Site

Nishinomiya-shi, 663-8501, Japan
Research Site

Sendai, 980-8574, Japan
Research Site

Shinagawa-ku, 142-8666, Japan
Research Site

Shinjuku-ku, 162-8655, Japan
Research Site

Tsukuba, 305-8577, Japan
Research Site

Yokohama, 241-8515, Japan
Research Site

CD Mexico, 04980, Mexico
Research Site

Guadalajara, 44670, Mexico
Research Site

Guadalajara Jalisco, 44280, Mexico
Research Site

Mexico City, 0 3100, Mexico
Research Site

México, 14080, Mexico
Research Site

México, 6760, Mexico
Research Site

Bacolod, 6100, Philippines
Research Site

Cebu, 6000, Philippines
Research Site

Cebu City, 6000, Philippines
Research Site

City of Muntinlupa, 1780, Philippines
Research Site

Iloilo City, 5000, Philippines
Research Site

Quezon City, 1101, Philippines
Research Site

Quezon City, 1112, Philippines
Research Site

San Juan City, 1500, Philippines
Research Site

Bialystok, 15-027, Poland
Research Site

Bydgoszcz, 85-796, Poland
Research Site

Lodz, 93-338, Poland
Research Site

Poznan, 60-192, Poland
Research Site

Warsaw, 02-781, Poland
Research Site

Wroclaw, 53-413, Poland
Research Site

Bukit Merah, 169610, Singapore
Research Site

Singapore, 119074, Singapore
Research Site

Singapore, 308433, Singapore
Research Site

Cape Town, 7570, South Africa
Research Site

Johannesburg, 2196, South Africa
Research Site

Pretoria, 0002, South Africa
Research Site

Pretoria, 0081, South Africa
Research Site

Soweto, 2013, South Africa
Research Site

Busan, 602-739, South Korea
Research Site

Daegu, 41404, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06273, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Barcelona, 08028, Spain
Research Site

Barcelona, 8035, Spain
Research Site

Granada, 18016, Spain
Research Site

L'Hospitalet de Llobregat, 08908, Spain
Research Site

Madrid, 28007, Spain
Research Site

Madrid, 28034, Spain
Research Site

Madrid, 28046, Spain
Research Site

Majadahonda, 28222, Spain
Research Site

Málaga, 29010, Spain
Research Site

Santiago de Compostela, 15706, Spain
Research Site

Seville, 41013, Spain
Research Site

Hsinchu, 300, Taiwan
Research Site

Taichung, 40447, Taiwan
Research Site

Taichung, 40705, Taiwan
Research Site

Tainan, 70403, Taiwan
Research Site

Tainan, 710, Taiwan
Research Site

Taipei, 10002, Taiwan
Research Site

Taipei, 11217, Taiwan
Research Site

Taoyuan, 00333, Taiwan
Research Site

Bangkok, 10210, Thailand
Research Site

Bangkok, 10330, Thailand
Research Site

Bangkok, 10400, Thailand
Research Site

Chiang Mai, 50200, Thailand
Research Site

Dusit, 10300, Thailand
Research Site

Hat Yai, 90110, Thailand
Research Site

Khon Kaen, 40002, Thailand
Research Site

Ankara, 06340, Turkey (Türkiye)
Research Site

Ankara, 06520, Turkey (Türkiye)
Research Site

Diyarbakır, 21280, Turkey (Türkiye)
Research Site

Istanbul, 34662, Turkey (Türkiye)
Research Site

Izmir, 35575, Turkey (Türkiye)
Research Site

Konya, 42080, Turkey (Türkiye)
Research Site

Malatya, 44280, Turkey (Türkiye)
Research Site

Bristol, BS2 8ED, United Kingdom
Research Site

Cardiff, CF14 2TL, United Kingdom
Research Site

Edinburgh, EH4 2XU, United Kingdom
Research Site

London, EC1A 7BE, United Kingdom
Research Site

London, SE1 9RT, United Kingdom
Research Site

London, SW17 0QT, United Kingdom
Research Site

Northampton, NN1 5BD, United Kingdom
Research Site

Nottingham, NG5 1PB, United Kingdom
Research Site

Warwick, CV34 5BW, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.